TB Alliance regimen development for multidrug-resistant tuberculosis

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):38-41. doi: 10.5588/ijtld.16.0069.


The recent approval of new tuberculosis (TB) drugs raises hope for new and more effective anti-tuberculosis treatment regimens. The Global Alliance for TB Drug Development (TB Alliance) is committed to ensuring that new anti-tuberculosis drugs fulfill the needs of patients, their families and the local health services that serve the communities. Here we present highlights of the TB Alliance's pipeline of regimen development, with novel regimens for patients with drug-susceptible, multidrug-resistant and extensively drug-resistant TB. The ongoing clinical trials (STAND, NC-005, Nix-TB and LIN-CL001) are outlined and their rationale and goals presented.

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Clinical Protocols
  • Diarylquinolines / therapeutic use
  • Dose-Response Relationship, Drug
  • Ethambutol / therapeutic use
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Fluoroquinolones / therapeutic use
  • Humans
  • Isoniazid / therapeutic use
  • Linezolid / therapeutic use
  • Moxifloxacin
  • Nitroimidazoles / therapeutic use
  • Pyrazinamide / therapeutic use
  • Randomized Controlled Trials as Topic
  • Research Design
  • Rifampin / therapeutic use
  • Tuberculosis, Multidrug-Resistant / drug therapy*


  • Antitubercular Agents
  • Diarylquinolines
  • Fluoroquinolones
  • Nitroimidazoles
  • pretomanid
  • Pyrazinamide
  • bedaquiline
  • Ethambutol
  • Linezolid
  • Moxifloxacin
  • Isoniazid
  • Rifampin